Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.

Anti-cancer drugs - 1 Jan 2015

Sun Zhenguo, Wang Zhou, Liu Xiangyan, Wang Dong

Abstract excerpt

Lung cancer is the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) is the most common pathological type of lung cancer, divided into squamous cell carcinoma and adenocarcinoma. Despite better techniques of surgery and improvement in adjuvant and neoadjuvant therapy, the median survival of advanced NSCLC is only 8-10 months. With increased understanding of molecular alternations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Discovery
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinase

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 25304988
DOI: 10.1097/CAD.0000000000000172

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.PMID 25304988Read ↗

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.Semantic proximity Read ↗

Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene.Semantic proximity Read ↗

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.Semantic proximity Read ↗

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read ↗

Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review.Semantic proximity Read ↗

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?Semantic proximity Read ↗

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.Semantic proximity Read ↗

Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.Semantic proximity Read ↗

Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLCSemantic proximity Read ↗

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.Semantic proximity Read ↗

Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non‑small cell lung cancer.Semantic proximity Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.